Cargando…

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis

BACKGROUND: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the ‘no evidence of disease activity’ (NEDA) definition should now include CLs. The aim of this study was to evaluate the NEDA3 + CL status in natalizumab- o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puthenparampil, Marco, Cazzola, Chiara, Zywicki, Sofia, Federle, Lisa, Stropparo, Erica, Anglani, Mariagiulia, Rinaldi, Francesca, Perini, Paola, Gallo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204617/ https://www.ncbi.nlm.nih.gov/pubmed/30386435 http://dx.doi.org/10.1177/1756286418805713

Ejemplares similares

Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2020)

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2023)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
por: Puthenparampil, Marco, et al.
Publicado: (2017)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Case Report: Para-infectious cranial nerve palsy after bacterial meningitis
por: Zanotelli, Giovanni, et al.
Publicado: (2022)

BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset
por: Puthenparampil, M., et al.
Publicado: (2017)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients
por: Piervincenzi, Claudia, et al.
Publicado: (2021)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort
por: Jaklin, Andreas K., et al.
Publicado: (2021)

Early red nucleus atrophy in relapse‐onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2020)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study
por: Riccardi, Alice, et al.
Publicado: (2021)

Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
por: Rinaldi, Francesca, et al.
Publicado: (2017)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis
por: Rotstein, Dalia, et al.
Publicado: (2022)

Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab
por: Ottenlinger, Florian M., et al.
Publicado: (2016)

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
por: Lefort, M., et al.
Publicado: (2022)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis
por: Puthenparampil, Marco, et al.
Publicado: (2017)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2017)

Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis
por: Pengo, Marta, et al.
Publicado: (2022)

D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive Disability
por: Riccardi, Alice, et al.
Publicado: (2019)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis
por: Cramer, Stig P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sejo8gglcdi9e9bgi9u0p0j0jb